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Abstract
The improvements in magnetic resonance imaging (MRI) technology and the concern
related to the increased cancer risk in patients with lymphoma, also due to radiation
exposure associated with imaging examinations, have led to the introduction of
whole-body MRI (WB-MRI) as a radiation-free alternative to standard imaging proce-
dures. WB-MRI seems a less histology-dependent functional imaging test than 18F-
fluorodeoxyglucose-positron emission tomography/CT (18F-FDG-PET/CT). In
patients with FDG-avid lymphomas, such as diffuse large B-cell lymphoma (DLBCL)
and Hodgkin lymphoma (HL), 18F-FDG-PET/CT remains the imaging reference stan-
dard for staging, with WB-MRI potentially being a complementary modality that
could replace CT, especially in young patients. On the other hand, WB-MRI is a valu-
able imaging procedure for lymphoma surveillance and in lymphomas with variable/
low FDG avidity and nonfollicular indolent lymphomas. The aim of this paper is to
discuss the current state of the art of WB-MRI in lymphoma by evaluating its diag-
nostic performance in different lymphoma subtypes: Hodgkin, aggressive, and indo-
lent lymphomas.
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1 | INTRODUCTION
Lymphoma accounts for about 5% to 6% of all malignancies.1 Hodgkin
lymphoma (HL) and non-Hodgkin lymphoma (NHL) are the third most
common cancers in children, with HL being the fourth most common
cancer in pregnancy.2,3 To date, contrast-enhanced CT (CECT) and
18F-fluorodeoxyglucose-positron emission tomography/CT (18F-FDG-
PET/CT) are both recommended for lymphoma staging, with the latter
being more accurate, mainly due to its higher sensitivity in displaying
extranodal locations.4 18F-FDG-PET/CT represents the reference
standard for staging and response assessment in FDG-avid lympho-
mas; CECT is recommended to image variably/low FDG-avid lympho-
mas.5 CECT is routinely included in lymphoma staging due to its
robustness in nodal size measurement, evaluation of compression or
thrombosis of central vessels, and discrimination between a single
mass and an aggregate of single nodes.5 For surveillance of patients
with stage I/II, the National Comprehensive Cancer Network (NCCN)
guidelines recommend clinical examination and blood test every 3 to
6 months for 5 years and imaging only if signs of disease relapse
occur, whereas CECT every 6 months for 2 years in stage III/IV
patients.6
Concerns have been raised on radiation exposure due to imaging
examinations and its association with increased risk of secondary can-
cer in patients with lymphoma.7,8 This has favored an emerging inter-
est for the use of whole-body magnetic resonance imaging (WB-MRI)
as a radiation-free alternative to standard imaging procedures.9,10 The
improvements in MRI technology have further sustained the inclusion
of WB-MRI among the diagnostic tools for patients with lymphoma.
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The actual role of WB-MRI in the diagnostic workup in lymphoma is
examined in the present review. The current state of the art of WB-
MRI and its diagnostic performance in different lymphoma subtypes,
namely, HL, aggressive lymphomas, and indolent lymphomas, is
discussed.
2 | WB-MRI: MAIN ASPECTS OF ITS USE IN
LYMPHOMA
WB-MRI provides images of the body from head to toe including
patient arms, although it generally covers from the vertex to midthigh.
There is no consensus on the best protocol for WB-MRI in lymphoma.
Different approaches have been proposed in previous studies includ-
ing unenhanced T1- and T2-weighted, short tau inversion recovery
and diffusion-weighted imaging (DWI) sequences.10,11 The “func-
tional” evaluation is based on DWI through the visualization and
quantification of the random Brownian motion of water molecules in
the biologic tissues, assessed by apparent diffusion coefficient
(ADC).12 However, there is no agreement on DWI parameters (b
values) to be used. Lymphoma is characterized by high cellularity and
elevated nuclear-to-cytoplasm ratio leading to restricted diffusion of
water molecules than in normal tissues, thus producing high signal
intensity on DWI and low ADC values, which help to easily identify
the sites of disease.13 Gradient-echo Dixon sequence has been more
and more used. This allows a homogeneous water/fat suppression
with great advantages for bone marrow imaging.14
Different WB-MRI criteria have been proposed for the evalua-
tion of lymph nodal involvement, in addition to standard dimen-
sional criteria (longest diameter > 1.5 cm).9 Lymph nodes can be
considered involved when DWI signal (a) has greater intensity than
that of spinal cord or muscles; (b) maintains high signal intensity at
higher b values, with restriction confirmed by low ADC or in the
presence of central necrosis, disregarding the dimension; and (c)
coalesced into large nodal mass.15 Nevertheless, no clear cutoff of
ADC values has been established to differentiate normal lymph
nodes from lymphoma in clinical practice. Further, although lymph
nodal ADC measurements have shown to be reproducible, it has
not been defined whether mean or minimum ADC values should be
employed.
In literature, excellent agreement (k = 0.82-1.00) between WB-
MRI and 18F-FDG-PET/CT has been reported for the detection of
both nodal and extranodal locations.16 WB-MRI at 1.5 and 3T
scanner have shown similar diagnostic performance for lymphoma
staging.17 WB-MRI seems to be slightly inferior to 18F-FDG-PET/
CT for staging FDG-avid subtypes, while it seems superior to both
18F-FDG-PET/CT and CECT in lymphomas with variable FDG avid-
ity.18,19 The reported results have led several authors to propose
WB-MRI as the optimal imaging tool for monitoring indolent lym-
phomas (i-NHLs) and aggressive lymphomas in complete remission,
as well.20
Despite its good diagnostic performance, WB-MRI has shown
weaknesses to evaluate small mediastinal and pulmonary hilar lymph
nodes due to artifacts on DWI by cardiac pulsation and breathing,
with miscalculation of ADC values.21 In addition, the characterization
of focal splenic lesions by WB-MRI can be challenging due to the
anisotropic physiologically restricted pattern of diffusion of normal
splenic parenchyma on DWI.22 Thus, a conjunction of DWI with stan-
dard morphologic WB-MRI images is needed to identify focal splenic
involvement.4
The administration of gadolinium-based contrast agents during
WB-MRI in lymphoma may improve the accuracy to identify paren-
chymal lesions. It seems particularly helpful in cases with high risk of
extranodal localizations.23,24 Conversely, some authors believe that
unenhanced morphologic evaluation with DWI is sufficiently effec-
tive. This is corroborated by the increasing awareness of gadolinium
accumulation in human tissues, whose clinical implication is still
unclear.25,26
WB-MRI acquisition timing is related to the MRI unit and imaging
protocol, ranging from 30 minutes to more than 1 hour, approxi-
mately. Overall, the whole procedure takes shorter time than 18F-
FDG-PET/CT—including the time between radiopharmaceutical injec-
tion and images acquisition.27,28 Further, Plathow et al highlighted the
potential economic impact of WB-MRI, since the total cost of WB-
MRI results lower than that of 18F-FDG-PET/CT,27 although the costs
might vary according to the different health care systems and
countries.
Regarding patient compliance, WB-MRI, 18F-FDG-PET/CT, and
CT are all well tolerated with high degree of patient acceptance.28,29
The sources of discomfort and/or anxiety of undergoing 18F-FDG-
PET/CT and CT are pain and fear for injection of radioactive sub-
stances or contrast media, fasting period, radiation exposure, and the
need to limit contact with people after 18F-FDG-PET/CT.28,29 On the
other hand, a major concern for patients undergoing WB-MRI is claus-
trophobia due to the anxiety of being for a long time in the closed
space of MRI machine, partly relieved by taking oral sedatives.28
Advantages and disadvantages in the use of the main imaging modali-
ties in patients with lymphoma are reported in Table 1.
3 | HODGKIN LYMPHOMAS
HL is subdivided into two main subgroups: classical HL representing
over 90% of HL, with high FDG uptake, and nodular lymphocyte-pre-
dominant HL, which typically shows indolent behavior and low if any
FDG uptake.30 18F-FDG-PET/CT has been included as standard imag-
ing modality for staging and posttreatment assessment in classical
HL.5 Moreover, PET scan has been extensively employed as interim
evaluation during chemotherapy for the early assessment of disease
response.31,32 Several studies have reported high accuracy of WB-
MRI for HL staging showing better agreement between WB-MRI and
18F-FDG-PET/CT in patients with HL than in those with NHL.22,33,34
In a prospective study on 140 lymphoma patients, Mayerhoefer et al
reported a strong agreement between WB-MRI and 18F-FDG-PET/CT
for staging HL, suggesting that WB-MRI could be a valuable alterna-
tive tool for lymphoma staging, especially in younger patients or in
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areas where 18F-FDG-PET/CT is not available.22 Albano et al com-
pared WB-MRI and 18F-FDG-PET/CT in staging 68 patients with
FDG-avid lymphomas, including 37 HLs.34 The agreement between
the two procedures was excellent (k = 0.92) in HL (concurrence in 35/
37, 95%). WB-MRI overstaged one patient with HL considering
involved a peri-aortic lymph node without FDG uptake and
understaged a patient with a lung lesion wrongly interpreted as a peri-
bronchial lymph node.34 In another study, the same authors have
recently reported that DWI could be helpful to differentiate
responder from nonresponder HL lesions on interim-WB-MRI during
ABVD treatment (Figure 1).35 Interestingly, Horger et al have demon-
strated a significant increase of ADC of responding lesions in success-
fully treated HL and NHL since early after the first chemotherapy
course whereas nonresponding lesions showed unchanged ADC
values. Size changes were also recorded although at a less marked
extent between responding and nonresponding lesions.36 Latifoltojar
et al recently confirmed the value of WB-MRI for the assessment of
both nodal and extranodal involvement in pediatric HL patients.37
However, they stressed that disease response might have been under-
estimated by WB-MRI in extranodal sites, making questionable the
use of this modality in place of standard examinations, namely, 18F-
FDG-PET/CT. Regarding standard MRI features, both T2 signal inten-
sity and contrast enhancement of lymphomatous lesions have a ten-
dency to decrease after treatment.38 However, these findings cannot
be used to differentiate responding from nonresponding lesions. The
reduction of T2 signal may be related to fibrotic stroma and collagen;
nevertheless, immature fibrotic tissue, necrosis, or edema can produce
an increase T2 signal limiting its utility in this setting.38
WB-MRI has also shown effectiveness to detect certain and
recently described complications, namely, the osteonecrosis, that may
occur in HL patients treated with chemotherapeutic regimens includ-
ing high doses of corticosteroids. Indeed, a proven association
between dose of steroids, courses of chemotherapy, and risk of
osteonecrosis has been reported.39,40 In this setting, WB-MRI is the
optimal imaging modality taking advantage of the well-established
excellent accuracy of MRI to early identify osteonecrosis and the
TABLE 1 Advantages and disadvantages in the use of the main
imaging modalities in patients with lymphoma
Technique Advantages Disadvantages
18F-FDG-PET/CT - Wide availability
- Functional evaluation
with FDG uptake
- Clear SUVmax cutoff
- Reproducibility
- Standard imaging
protocol
- Radiation exposure
- No FDG uptake of
some lymphomas
- Long examination
time
CT - Wide availability
- Short acquisition
time
- High spatial
resolution
- Reproducibility
- Standard imaging
protocol
- Radiation exposure
- Contrast injection
- Only morphologic
evaluation
WB-MRI - No radiation
exposure
- Not necessary
contrast injection
- High contrast
resolution
- Bone marrow
evaluation
- Functional evaluation
with DWI
- Less histology
dependent
- Feasible in pregnancy
- No clear ADC cutoff
values
- Lower availability
- Limited accuracy for
lung evaluation
- Patient anxiety due
to claustrophobia
- Long examination
time
Abbreviations: 18F-FDG-PET/CT, 18F-fluorodeoxyglucose-positron
emission tomography/CT; ADC, apparent diffusion coefficient; DWI,
diffusion-weighted imaging; WB-MRI, whole-body magnetic resonance
imaging.
F IGURE 1 A 31-year-old man with Hodgkin lymphoma (HL). Pre-treatment coronal short tau inversion recovery (STIR) (A), postcontrast
coronal 3D-GRE T1-weighted (B), coronal maximum intensity projection (MIP) grey-scale inverted diffusion-weighted imaging (DWI) (C), and axial
apparent diffusion coefficient (ADC) map (D) show multiple nodal locations in mediastinal and supraclavicular regions (A,B,C; arrows), with very
low ADC values (D, arrow); ADC map after two courses of ABVD treatment (E) shows the substantial size reduction of mediastinal lymph nodes
that also present high ADC values (arrowhead)
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possibility to investigate all skeletal segments with a single test
(Figure 2).41,42
In HL patients, WB-MRI can be considered a complementary
imaging modality that could take the place of CECT in diagnostic
workup and lymphoma surveillance, especially in young patients, but,
to date, WB-MRI will hardly replace 18F-FDG-PET/CT for staging and
response assessment of HL.
4 | AGGRESSIVE LYMPHOMAS
The aggressive lymphoma subgroup includes several subtypes charac-
terized by rapid tumor growth and the usual need of immediate treat-
ment. Diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma
(MCL), Burkitt lymphoma, and peripheral T-cell lymphomas represent
the main aggressive subtypes. DLBCL is the most common accounting
for approximately 30% of all NHLs.43,44 DLBCL, like most aggressive
lymphomas, displays high FDG uptake.45 Distinct features are shown
by MCL, which accounts for approximately 2% of all NHLs, and, as
opposed to DLBCL, has variable behavior on 18F-FDG-PET/CT.46,47
Several studies have investigated the diagnostic performance of
WB-MRI in aggressive lymphomas in comparison with 18F-FDG-PET/
CT and/or CECT. Most of these works included different lymphoma
subtypes.18,48-51 Lin et al have demonstrated the value of WB-MRI in
diagnostic workup of DLBCL, showing whole agreement between
WB-MRI and 18F-FDG-PET/CT in staging 93% of patients.51
Abdulqadhr et al compared WB-MRI with 18F-FDG-PET/CT for stag-
ing of 31 patients, including 18 aggressive subtypes (13 DLBCLs,
three primary mediastinal B-cell lymphomas, one anaplastic large cell
lymphoma, and one T-cell lymphoma). Patients were uniformly staged
by both modalities with perfect agreement (18/18, 100%) in stage
definition (Figures 3 and 4).52 Similarly, Mayerhoefer et al demon-
strated a quite good agreement (93%) between WB-MRI and 18F-
FDG-PET/CT in a series of 28 DLBCLs.22 MCL is often staged with
CECT, due to the variable FDG uptake in MCL. However, CECT pro-
vides just morphological information, and it has lower sensitivity for
the assessment of bone marrow involvement (BMI) than WB-
MRI.22,47 A few studies have compared WB-MRI and CECT stressing
the higher accuracy of WB-MRI compared with CECT. This is associ-
ated with the well-known advantages of WB-MRI, namely, its radia-
tion-free imaging modality with no need of contrast injection.49,50,53
In particular, Kwee et al compared WB-MRI and CECT in 104
patients, including 34 DLBCLs and eight MCLs, showing an agree-
ment in staging definition for approximately two-thirds of patients.
WB-MRI allowed a correct upstaging in almost 30% of patients due
to a better evaluation of BMI, although it led to an incorrect down-
staging in 6.7%, due to omitted detection of some pleural/lung and
lymph nodal involvements.49
The evaluation of BMI is a crucial step in lymphoma staging, and it
is usually performed through bone marrow biopsy (BMB), at least in
NHLs.5 WB-MRI is well established to investigate diffuse and focal
BMI, and several reports have investigated WB-MRI performance to
detect lymphomatous BMI.19,53 In aggressive lymphomas, WB-MRI
has shown to be accurate especially to identify focal BMI, which can
be occasionally missed by BMB.54 Notably, Adams et al have shown
an increased risk of disease progression and death in DLBCL patients
with WB-MRI positive for lymphomatous BMI in comparison with
WB-MRI negative patients, suggesting a potential prognostic role of
WB-MRI in DLBCL patients with negative BMB.55 However, the accu-
racy of DWI and ADC values to detect BMI and to assess treatment
response is still an issue of controversy, with some authors reporting
no significant differences between lymphomatous BMI and normal
bone marrow while others support the possible role of ADC values to
assess short-term response to treatment.19,56
The potential role of WB-MRI to assess treatment response in
DLBCL has been addressed in several studies. Early in 2011, Lin et al
reported a significant increase of ADC in enlarged masses persisting
after therapy.57 Similar results were obtained by De Paepe et al in 14
aggressive lymphoma patients (12 DLBCLs and two T-cell lymphomas)
undergoing WB-MRI at 3T MRI before therapy, after two courses and
at therapy completion.58 ADC measurements allowed to differentiate
responder from nonresponder nodal/extranodal lesions with 100%
negative predictive value and 86% positive predictive value, also with
significant correlation between ADC changes and progression free
survival (P < .05).58 Conversely, size changes of the lesions did not
enable to correctly assess early treatment response. The reported
F IGURE 2 A 28-year-old woman with Hodgkin lymphoma
(HL) treated by BEACOPP. Coronal T1-weighted (A) and short tau
inversion recovery (STIR) images (B) after treatment show
osteonecrotic lesions of both femurs (arrows)
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results support the value of DWI-MRI with ADC measurement for the
short-term response evaluation in lymphoma.58 Mayerhoefer et al in a
recent study on 64 patients (22 aggressive lymphomas) proved that
WB-MRI is almost equal to 18F-FDG-PET/CT for both response
assessment after few (one to three therapy cycles) chemotherapy
courses and at end-of-treatment evaluation.48 The authors propose
a possible correlation between cell density (higher diffusion restric-
tion on DWI and lower ADC values) and glucose consumption
(FDG uptake).59 Indeed, the possible correlation between DWI/
ADC and lymphoma proliferation remains a controversial issue. Pre-
vious studies have shown no correlation between ADC values and
SUVmax of lymphoma sites in both NHL and HL.
35,60 Conversely, a
recent study has shown an inverse correlation between ADC and
KI-67 index.61 Future radiomic studies may clarify the degree of
correlation among MRI, 18F-FDG-PET/CT, CECT and histology, cell
proliferation, and even molecular features of various aggressive
lymphoma subtypes.
The prognostic impact of BMI in DLBCL patients has been dis-
cussed for years, and no univocal conclusions have been reached yet.
In the future, the widespread use of WB-MRI in patients with lym-
phoma could be helpful to clarify this controversial point.
5 | INDOLENT LYMPHOMAS
The indolent lymphoma (i-NHL) subgroup includes slow-growing
malignancies characterized by prolonged natural history and generally
few if any clinical symptoms.62 Follicular lymphoma (FL) is the most
common i-NHL and represents more than 20% of all NHLs. Generally,
immediate treatment is not needed for i-NHLs, with watchful waiting
(WW) being considered a reasonable strategy in most cases. Treat-
ment is delayed as much as possible, and monitoring these patients
with imaging follow-up, laboratory tests, and clinical examinations is
the main recommendation.63,64 Imaging during WW is performed
F IGURE 3 A 62-year-old man with
peripheral T-cell lymphoma. Coronal
maximum intensity projection (MIP)
grey-scale inverted diffusion-weighted
imaging (DWI) (A), axial DWI (B,D,F), and
axial postcontrast 3D-GRE T1-weighted
images (C,E,G) show multiple extranodal
locations (arrows): prevescical (A,B,C),
subcutaneous (D,E), and pulmonary (F,G).
Also note the enlargement of the spleen
(A; asterisk)
F IGURE 4 A 23-year-old man with
relapsed mantle cell lymphoma (MCL)
after chemotherapy and transplant.
Coronal short tau inversion recovery
(STIR) (A), coronal postcontrast 3D-GRE
T1-weighted (B), axial postcontrast 3D-
GRE T1-weighted (C), axial postcontrast
T1-weighted (D), and sagittal
postcontrast T1-weighted images
(E) show meningeal recurrence in thoracic
medullary cord (curved arrows). Also note
the osteonecrotic lesions in the right
humeral head and in both femoral heads
(A; arrows) due to the high doses of
corticosteroids received by the patient
after transplant
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through 18F-FDG-PET/CT and/or CECT for FDG-avid lymphomas like
FL, whereas CECT is recommended for non–FDG-avid subtypes.65,66
Previous studies have demonstrated that WB-MRI is a useful diag-
nostic approach for i-NHL (Figure 5), with reports documenting that
WB-MRI has equal or even greater accuracy than CECT in staging
workup.49,67 Balbo-Mussetto et al included 16 i-NHLs (13 FLs and
three MCLs) in their series of 41 patients, who underwent WB-MRI,
CECT, and 18F-FDG-PET/CT.67 In their study, WB-MRI was superior
to CECT, especially to detect extranodal locations, with some false
negatives nodes in mediastinum, which is the intrinsic weakness of
WB-MRI.21 Kwee et al compared WB-MRI without DWI, WB-DWI-
MRI, and CECT in 108 patients; almost half of them were i-NHLs.49
WB-MRI allowed to obtain the same stage as with CECT, without any
reported advantage by adding DWI. WB-MRI showed to be more
accurate to detect BMI but missed some involved lymph nodes and
some lung/pleural and liver lesions. Regarding focal hepatic lesions,
the main problem of WB-MRI was the wrong interpretation of hem-
angiomas. In this setting, contrast media injection could be helpful, as
demonstrated for the detection of splenic HL involvement.24 About
the utility of DWI, several authors have proven its key role in WB-
MRI staging of lymphomas. Littooij et al confirmed the strength of
WB-DWI-MRI in the detection of residual disease after therapy. This
is especially true if the procedure includes the quantitative assess-
ment of diffusion restriction with ADC that gives information regard-
ing tissue viability.68 In their series of 31 patients with lymphoma,
Abdulqadhr et al found disagreements between WB-MRI and 18F-
FDG-PET/CT in three i-NHL patients, with WB-MRI allowing a cor-
rect upstaging of disease.52 Stecco et al found an excellent agreement
between WB-MRI and 18F-FDG-PET/CT in staging gastrointestinal
lymphomas in a series of 17 patients including 12 i-NHLs.69 In a series
of FL patients, Mayerhoefer et al reported a strong agreement (26/28,
93%) between WB-MRI and 18F-FDG-PET/CT.22 The same authors
demonstrated that the sensitivity of WB-MRI (94.4%) is much higher
than that of 18F-FDG-PET/CT (60.9%) and CECT (70.7%) in lymphoma
subtypes with variable FDG avidity, in particular mucosa-associated
lymphoid tissue (MALT) lymphomas.22 Furthermore, in a small series
of patients with MALT lymphoma treated with rituximab, both quanti-
tative evaluation obtained on 18F-FDG-PET/CT (SUVmax and SUVmean)
and WB-DWI-MRI (ADCmin and ADCmean) seemed to be able to pre-
dict complete remission after therapy.70 Of note, Mosavi et al evalu-
ated 50 patients with lymphoma (12 HLs, 29 aggressive lymphomas,
and nine i-NHLs) by WB-MRI and reported significantly lower ADC
values in i-NHLs than in other lymphomas. This suggests the potential
application of WB-MRI to detect the transformation of i-NHLs in
aggressive NHL.71 As previously mentioned, both 18F-FDG-PET/CT
and WB-MRI have shown to be valid tools to detect BMI in aggressive
lymphomas. However, this does not hold true in i-NHLs, where both
18F-FDG-PET/CT and WB-MRI are considered complementary imag-
ing modalities to BMB.19,72
It should be stressed that 18F-FDG-PET/CT is pivotal in FL man-
agement. 18F-FDG-PET/CT is the most accurate modality for FL stag-
ing73 and allows to identify FL transformation presenting with
significantly increased FDG uptake in transformed areas.74 This is
especially crucial in FL that shows the highest risk of secondary trans-
formation among all i-NHLs.75
WB-MRI should be considered as a valid imaging tool in disorders
with long life expectancy like nonfollicular i-NHLs, potentially
replacing diagnostic examinations that expose to ionizing radiations.
This could be helpful in the effort to reduce toxicity and cancer risk
related to treatments.
6 | FUTURE PERSPECTIVES
The introduction of 18F-FDG-PET/MRI is of great interest for its
potential application in lymphoma, although its role has not been fully
established. This modality enables to reduce radiation exposure com-
pared with 18F-FDG-PET/CT, and it represents a valuable option
especially in pediatric patients suffering from lymphoma. Besides the
F IGURE 5 A 62-year-old man with follicular lymphoma (FL). Coronal maximum intensity projection (MIP) grey-scale inverted diffusion-
weighted imaging (DWI) (A), axial postcontrast 3D-GRE T1-weighted (B,D,F), and axial DWI (C,E,G) show multiple nodal locations (arrows) in right
common iliac level (A,B,C), celiac trunk (A,D,E), and left laterocervical region (A,F,G)
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advantage of the high contrast resolution, MRI with the use of both
DWI and PET findings allows to obtain a combined “functional” evalu-
ation of cell density and metabolic activity.76,77 Indeed, the addition
of DWI to PET/MRI is still debatable in lymphoma. A recent study in
34 lymphoma patients demonstrated that 18F-FDG-PET/MRI without
DWI and 18F-FDG-PET/CT have similar accuracy in HL and aggressive
NHL.78 However, the inclusion of DWI in 18F-FDG-PET/MRI protocol
allowed to achieve higher diagnostic performance than 18F-FDG-PET/
CT, especially in MALT lymphomas.78 Conversely, Afaq et al did not
report any improvement of diagnostic performance of 18F-FDG-PET/
MRI by adding DWI.79 Hermann et al evaluated 61 patients reporting
similar diagnostic performance of 18F-FDG-PET/MRI and 18F-FDG-
PET/CT.80 This led the authors to postulate that WB-MRI may have a
role in specific settings such as imaging surveillance and i-NHLs.80
New interesting perspectives include also the application of tex-
ture analysis on WB-MRI performed in lymphoma patients, although
few studies have focused on this tool. Radiomics extracts a large num-
ber of image features, which can be “seen” only by computers, being
beyond human perception.81 Texture analysis can quantify the spatial
pattern and arrangement of pixel intensities in medical images all-
owing to provide crucial information regarding tumor phenotype,
thereby highlighting intratumor heterogeneity. Several works have
demonstrated that this heterogeneity could have remarkable implica-
tions on tumor prognosis being a typical pattern of malignancies asso-
ciated with aggressive behavior and poor response to therapies.82,83
In a recent study on 28 patients with NHL, De Paepe et al have dem-
onstrated that first-order ADC texture analysis on WB-DWI-MRI at
3T can increase the accuracy of lymph node characterization in com-
parison with ADCmean.
84 Wu et al have explored the applicability of
texture analysis on postcontrast T1-weighted MRI images to differen-
tiate FL and DLBCL reporting high diagnostic accuracy to distinguish
these subtypes.85 Thus, this tool could be potentially helpful to early
identify a transformed lymphoma during imaging follow-up of FL.
However, there is still poor knowledge on this topic, and more studies
are needed to clarify the practical use of radiomics applied to the dif-
ferent imaging techniques.
7 | CONCLUSIONS
WB-MRI is an important novel diagnostic tool in lymphoma. However,
its precise role in diagnostic workup has not been clearly defined.
WB-MRI seems a less histology-dependent functional imaging test
than 18F-FDG-PET/CT. Moreover, it does not require radiation expo-
sure. In patients with FDG-avid lymphomas, such as DLBCL and HL,
18F-FDG-PET/CT remains the imaging reference standard for staging,
with WB-MRI potentially being a complementary modality that could
replace CECT, especially in young patients. On the other hand, WB-
MRI is a valuable imaging procedure for lymphoma surveillance, in
lymphomas with variable/low FDG avidity and nonfollicular indolent
lymphomas.86 According to the directive 2013/59 by the European
Union,86 whether a radiation-free imaging modality guarantees the
same diagnostic results, it should always be preferred. Based on this
recommendation, the use WB-MRI should be further explored and
viewed with particular interest by the scientific community to define
the ideal place of WB-MRI in diagnostic imaging pathway for patients
with lymphoma.
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